Medication info
Oldifil 5/40/12.5 mg

Oldifil 5/40/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
Light yellow round film-coated tablet
Packaging
30 tablets (10 tablets/Alu-Alu X 3)
Approval status
Active

MFDS item code 201903159 · Approved 2019.05.15 · Insurance code 693903000

Summary

Main use
Treatment of essential hypertension not controlled with concomitant amlodipine and olmesartan
Who takes it
Adults · Children
Adult dose
Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy) be adjusted before administering this medicine; however, direct switching to this medicine may be considered when blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil. The maximum dose of this medicine is 10/40/25mg as amlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. Recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment For patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min), the maximum dose of this medicine is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose of this medicine in patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Older adults (65 years and older) Treatment should generally be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. As there is very limited experience with the use of this medicine in older adults 75 years of age and older, careful monitoring is required when it is administered.
Child dose
Under 18 years of age: Use of this medicine is not recommended.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with concomitant amlodipine and olmesartan

  • Essential hypertension
View approved original text

This is a combination therapy with Amlodipine and Olmesartan Medoxomil for the treatment of difficult-to-treat essential hypertension. Essential hypertension refers to the condition where blood pressure is elevated without a specific cause. In this case, Amlodipine helps lower blood pressure by dilating blood vessels, while Olmesartan Medoxomil helps manage blood pressure by inhibiting the action of hormones that cause blood pressure elevation. However, there may be instances where blood pressure is not adequately controlled even with the combination therapy of these two medications. In such cases, additional treatment methods or changes in medications may be necessary. These drugs are used to effectively manage blood pressure in patients with essential hypertension.

How to take

Adult dose

Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy) be adjusted before administering this medicine; however, direct switching to this medicine may be considered when blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil. The maximum dose of this medicine is 10/40/25mg as amlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. Recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment For patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min), the maximum dose of this medicine is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose of this medicine in patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Older adults (65 years and older) Treatment should generally be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. As there is very limited experience with the use of this medicine in older adults 75 years of age and older, careful monitoring is required when it is administered.

Child dose

Under 18 years of age: Use of this medicine is not recommended.

Precautions

This medication should not be taken during the second and third trimesters of pregnancy as it can cause serious harm to the fetus and newborn. If pregnancy is confirmed, this medication should be discontinued immediately. Patients who are allergic or hypersensitive to this medication or any of its components, pregnant or breastfeeding women, patients with severe hypotension, and patients with significant renal or hepatic impairment should not receive this medication. Patients with decreased blood volume, impaired renal function, liver disease, and heart valve disease should use this medication with caution and monitor closely for symptoms such as hypotension or worsening renal function. Since this medication lowers blood pressure, it may cause dizziness or orthostatic hypotension, so caution is advised when driving or operating machinery. During treatment with this medication, regular tests should be conducted to monitor electrolyte levels and renal function, particularly considering the risk of elevated or decreased potassium levels. This medication can interact with other drugs, so especially when used in combination with lithium, non-steroidal anti-inflammatory drugs (NSAIDs), and other antihypertensives, consultation with a physician or pharmacist is necessary. The hydrochlorothiazide component can make the skin more sensitive to sunlight, so caution should be taken regarding UV protection during treatment, and if symptoms of photosensitivity occur, the medication should be discontinued immediately and advice should be sought from a specialist. This medication is not recommended for pediatric patients under 18 years of age as its safety and efficacy have not been established. In the elderly, the body's response to the medication may vary due to decreased renal and hepatic function, so treatment should start at lower doses and dose adjustments should be made cautiously. In cases of overdose, severe hypotension and heart dysfunction may occur, necessitating immediate medical attention for appropriate treatment. This medication should be stored out of reach of children and kept protected from direct sunlight and moisture.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, hypersensitivity to stimuli, anxiety, mood changes, sleep disturbances, neurological abnormalities, orthostatic dizziness, syncopal episodes, taste disorders, hypertonia, sensory loss, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremor, visual disturbances, reduced tear production, worsening of myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle spasm, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, increased urinary frequency, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, weakness, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial edema, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, increased gamma-glutamyl transferase, increased alanine aminotransferase, increased aspartate aminotransferase, elevated liver enzymes, increased serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption-like intestinal disease, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, angioedema, eczema, limb pain, mild decrease in mean hemoglobin and hematocrit levels, chronic malabsorption syndrome, acute respiratory distress syndrome, acute angle-closure glaucoma, choroidal effusion, acute hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Light yellow round film-coated tablet

Package unit

30 tablets (10 tablets/Alu-Alu X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.